Hepatitis C virus (HCV) infection is often asymptomatic in its early stages, so many people are unaware they live with the virus. Access to confirmatory molecular testing remains limited in remote, correctional and low-resource healthcare settings. Rapidly expanding access to testing is essential to closing the persistent gap between diagnosis and initiating highly effective curative treatments that can reduce morbidity and mortality. To help address this challenge, ZiP Diagn
Malaria is often discussed in statistics - case numbers, death rates, progress toward elimination. But behind those numbers are lived experiences that tell a more urgent story.
